AMGN Jan 2026 390.000 call
| Previous close | 18.61 |
| Open | 18.61 |
| Bid | 15.00 |
| Ask | 19.00 |
| Strike | 390.00 |
| Expiry date | 2026-01-16 |
| Day's range | 18.61 - 18.61 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
ZacksTop Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
PR NewswireNEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared
